Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 560-565, March 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wibe, E.
Right arrow Articles by Lindmo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wibe, E.
Right arrow Articles by Lindmo, T.

Inhibitory Effects of the New Mitotic Inhibitor 5-Chloropyrimidin-2-one and of Vincristine on Human Cells in Vitro1

Einar Wibe, Reidar Oftebro, Terje Christensen, Soren G. Laland, Erik O. Pettersen and Tore Lindmo

Departments of Tissue Culture [E. W., R. O., T. C., E. O. P.] and Biophysics [T. L.], Norsk Hydro's Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, and Department of Biochemistry, University of Oslo, Blindern, [S. G. L.] Oslo 3, Norway

By means of time-lapse microcinematography, metaphase arrest was studied in synchronized NHIK 3025 cells in contact with 5-chloropyrimidin-2-one (NY 3000) or vincristine. A dose-dependent prolongation of mitosis was found for both substances, and the fraction of cells able to escape mitotic arrest declined gradually as the concentration of NY 3000 or vincristine was increased. Significant prolongation of metaphase was observed after treatment with 0.5 mM NY 3000 or vincristine (0.5 ng/ml; 0.54 nM), while total block in metaphase was achieved with 8 mM NY 3000 or vincristine (16 ng/ml; 17.3 nM).

The inactivating effect was measured as loss of colonyforming ability after continuous exposure for 12 to 14 days. NY 3000 (0.75 mM) brought total inactivation, although the prolongation of metaphase still was small at this concentration of NY 3000. Vincristine at concentrations that cause great prolongation of metaphase still permitted formation of colonies.

Both drugs demonstrated dose-dependent prolongation of interphase at concentrations entailing complete metaphase block. The phase specificity of the interphase action on synchronized cells was measured by pulsed incorporation of [3H]thymidine combined with a registration of time of entry into metaphase. NY 3000 resulted in a prolongation of all stages of interphase. The interphase effect of vincristine was reflected in a delay in G2. This was confirmed by flow cytometric recording of DNA distributions.

These results reveal that the metaphase-arresting agents NY 3000 and vincristine act also in the interphases of proliferating cells. However, the mechanism behind the interphase effect seems to be different for the two drugs.

1 Supported by grants from The Norwegian Cancer Society and The Norwegian Research Council for Science and the Humanities.

Received 8/15/77. Accepted 11/28/77.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.